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Abstract
A ‘Down Syndrome critical region’ (DSCR) sufficient to induce the most constant phenotypes of Down syndrome (DS) had
been identified by studying partial (segmental) trisomy 21 (PT21) as an interval of 0.6–8.3 Mb within human chromosome 21
(Hsa21), although its existence was later questioned. We propose an innovative, systematic reanalysis of all described PT21
cases (from 1973 to 2015). In particular, we built an integrated, comparative map from 125 cases with or without DS fulfilling
stringent cytogenetic and clinical criteria. The map allowed to define or exclude as candidates for DS fine Hsa21 sequence
intervals, also integrating duplication copy number variants (CNVs) data. A highly restricted DSCR (HR-DSCR) of only 34 kb on
distal 21q22.13 has been identified as the minimal region whose duplication is shared by all DS subjects and is absent in all
non-DS subjects. Also being spared by any duplication CNV in healthy subjects, HR-DSCR is proposed as a candidate for the
typical DS features, the intellectual disability and some facial phenotypes. HR-DSCR contains no known gene and has
relevant homology only to the chimpanzee genome. Searching for HR-DSCR functional loci might become a priority for
understanding the fundamental genotype-phenotype relationships in DS.
Introduction
The concept that the main symptoms and signs of Down syn-
drome (DS) may be caused by overexpression of one or a few
genes located on a delimited, small region on human chromo-
some 21 (Hsa21) has had changing fortunes in the last decades.
Since the fundamental discovery of Lejeune et al. (1), we know
that Hsa21 is present in an extra copy in the cells of subjects
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with DS (trisomy 21). While it is widely accepted that excess ge-
netic material from Hsa21 is responsible for the typical picture
of DS in particular intellectual disability (ID), cardiovascular de-
fects and craniofacial dysmorphisms (2), to date there is no
pathogenetic model linking specific structural and functional
aspects of Hsa21 to DS picture. For most of the Hsa21 loci that
were studied, the overexpression model, that is the excess of
gene products in a 3:2 ratio with respect to the normal cells ex-
pected by the additional Hsa21 template, has proven to be true
(2–5). In addition, several genes on Hsa21 are known to have
functions biologically consistent with pathways known to be al-
tered in DS, in particular brain development and function, oxi-
dative metabolism and one-carbon pathway (6). However, the
actual correlation of individual Hsa21 genes to DS still remains
hypothetical in humans and has currently not led to therapeutic
success by rationally targeting functions encoded by Hsa21
genes (7).
Natural occurrence of partial (segmental) trisomy 21 (PT21),
the duplication of only a delimited segment of Hsa21 associated
or not to DS, was first reported by Ilbery et al. (8) as ‘incomplete
trisomy’ and is considered to be exceptional or extremely rare
(9,10). Approximately 200 cases have actually been reported in
literature in comparison to an estimated 5.8 million people with
DS in the world (6). However, this condition is invaluable in pro-
viding strong evidence that not all Hsa21 loci are required for
the manifestation of DS and at the same time offers a powerful
way to ‘detect the culprits among so many innocents’ (11).
Indeed, from a general biological and pathogenic point of view,
it is reasonable that overexpression of a certain fraction of
genes may be tolerated: ‘Surely, most of the genes do not pro-
duce harm when in triplicate, because trisomic children would
not survive at all. Few of the accelerated reactions are danger-
ous’ (11). As a recent remarkable example (12), a terminal dupli-
cation of at least 5 Mb on distal 21q22.3 including 77 protein-
coding genes (30% of all protein-coding Hsa21 genes) was not re-
lated to an abnormal phenotype (Hsa21 interval 41.6–46.6 Mb on
GenBank sequence NC_000021.9; all chromosomal coordinates
are adjusted in this work to the current Genome Reference
Consortium (GRC) human genome assembly GRCh38, or hg38,
December 2013). Similarly, while this work was in revision, a
new case of a 4.4 Mb interstitial duplication on 21q22.2q22.3
(39 612 165–43 981 027 interval in hg38), including 51 genes of
which 7 are in the Online Mendelian Inheritance in Man (OMIM)
Genetic Morbid Map, was reported both in a mother with a com-
pletely normal clinical picture and her female fetus with no dys-
morphism and normal psycho-motor development at two years
of age (13). In addition, overexpression of one gene might com-
pensate overexpression of another gene present in the dupli-
cated chromosome (e.g. overexpression of RCAN1, also known
as DSCR1, may compensate damage induced by overexpression
of APP, both genes being located on Hsa21) (14). Therefore, no ef-
fort should be spared to undertake a systematical investigation of
partial trisomies in order to focus on the possibility that a low
number of genes conserved in the segments shared by DS sub-
jects may have a significant role in the DS pathogenesis. It is nec-
essary at this point to briefly review the rise and fall of the
concept of a ‘critical’ region for DS on Hsa21 to justify this study.
In the first reports of PT21 (8,15,16), it was impossible to
identify which subregion of Hsa21 was lacking. Actually, at that
time, it was the phenotype to guide the interpretation of the
cases, due to difficulties in identifying the small G-group super-
numerary chromosome seen in DS as Hsa21 itself (17,18). Since
the introduction of a worldwide accepted banding method in
the human cytogenetic analysis in the early 1970s (19,20), it be-
came possible to demonstrate that children with a phenotype
indistinguishable from DS appeared to have only a specific por-
tion of Hsa21 rather than a complete Hsa21 long arm (21q).
Hsa21 short arm (21p) is considered genetically empty in prac-
tice, as shown by centric fusion (leading to robertsonian translo-
cation) in which the loss of 21p is consistent with a DS
phenotype indistinguishable from the one due to free trisomy
21 if the 21q dose is unbalanced (16,21) and with no clinical con-
sequences if 21q dose is balanced (18,22,23). The main mecha-
nisms leading to this so-called ‘partial’ or ‘segmental’ trisomy
were described as discordant segregation of interstitially de-
leted chromosomes 21; translocations involving segments of
21q; tandem translocations with an incomplete long arm of rep-
licated Hsa21 (24).
On these bases, in 1974 Niebuhr was the first to put forward
the hypothesis (25), by reviewing 14 previously described cases
with tandem translocations of G-group chromosomes and re-
porting a new one, that ‘trisomy of a rather delimited segment
on chromosome No. 21 is essential for the development of typi-
cal features in Down’s syndrome’, suggesting that ‘the very dis-
tal segment (21q22)’ (17.4 Mb) ‘may be pathogenetic in Down’s
syndrome’, thus already excluding that 65% of Hsa21 (total
length 46.7 Mb) may give a fundamental contribution to the very
basic features of DS.
In the subsequent 20 years, several single cases as well as
case series of PT21 were reported. The development of fluores-
cence in situ hybridization (FISH) techniques (26) allowed a more
detailed description of the duplicated 21q segments associated
to DS culminating in the early 1990s in the suggestion that a de-
limited sequence interval on Hsa21 overlapping among differ-
ent cases contributes significantly to the basic phenotype
characteristic of trisomy 21. In particular, the data of Rahmani
et al. (27) (two cases, D21S17-ETS2 interval,<3 Mb size), McCor-
mick et al. (28) (16 cases, D21S55-COL6A1, 8.3 Mb) as well as Dela-
bar et al. (29) (20 cases, D21S55-proximal to ERG, 0.6 Mb)
converged toward a region within 21q22 and restricted up to
0.6 Mb, from 37.7 to 38.3 Mb on Hsa21.
The first time that the term ‘Down Syndrome critical region’
(DSCR) was used appears to have been in Rahmani et al. (30); the
terms ‘Minimal Chromosomal Region’ (MCR) (28), ‘Down
Syndrome minimum critical region’ (DCR) (OMIM entry #190685)
or ‘Down Syndrome minimal region’ (31) have also been used.
Subsequently, in the naming of genes believed to be localized in
the DSCR, the ‘C’ in the acronym was sometimes meant as ‘criti-
cal’ and sometimes ‘candidate’ (32). Currently, although the
concept itself of ‘DSCR’ is questioned (see below), the term ‘criti-
cal’ has remained prevalent in the gene nomenclature and bio-
medical literature. This appears to be adequate because, if
existing, the DSCR concept should indicate a region causing
most critical, shared symptoms/signs of DS, rather than a re-
gion candidate for causing the (whole) phenotype of DS. The
DSCR concept led to a flourishing of structural and functional
studies of its content (33).
Korenberg et al. (34) argued against a single DSCR, because in
3 of the 16 cases, they reported only proximal duplications of 21
were observed; Antonarakis (10) observed in this respect that
more cases were necessary to clarify the contributions of differ-
ent Hsa21 regions to DS phenotypes. It is very important that in
several cases of PT21 the karyotype was reported as normal but
the observation of a phenotype strongly suggestive of DS
prompted further studies revealing subtle duplication of a
Hsa21 region [e.g. Scott et al. (35) and so on].
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At the end of the 1990s, the availability of the nucleotide se-
quence of Hsa21 (36) as well as methods with higher resolution
such as Array Comparative Genomic Hybridization (CGH) have
allowed the obtainment of new valuable data, along with the
continuing report of new PT21 cases. Two landmark studies
were published in 2009 (37,38), each reporting results for an un-
precedented number of subjects presenting with this condition,
in particular 16 (37) and then 30 cases (38), including both new
(12 and 9, respectively) and previously described cases.
Although both studies clearly showed associations of specific
Hsa21 regions to distinct DS phenotypes, they were not focused
on the search of a ‘core’ DSCR, because of the observation that
one single region cannot explain all DS phenotypes in all sub-
jects. As a matter of fact, since 2009, there has not actually been
another systematic attempt to identify a restricted DSCR and
further analysis on the subject has been explicitly considered
unwarranted by some authors (39). However, the subject to date
has not yet been thoroughly investigated following basic criteria
allowing to reach definite conclusions, in particular by collect-
ing the largest possible number of cases and by computerizing
all the data, as it was proposed since 1996 (40).
We propose here a systematic reanalysis of all described
cases with PT21 that is innovative under several aspects. First,
while previous works have always focused on a limited number
of cases, we have systematically searched for and compared
any available case published from 1973 (just following the intro-
duction of human chromosome banding) to 2015. An accurate
bibliographical search has been performed to include any report
of interest. We have also largely exploited the availability of a
Hsa21 detailed physical map to which consistently anchor data
produced through several decades by many different cytoge-
netic methods. For this reason, we have applied several compu-
tational biology methods to establish a common framework
and then used it to build our original integrated, Hsa21 compar-
ative map of PT21 in humans. In addition, we put forward the
concept of an ‘exclusion map’, in addition to that of a ‘candidate
map’, accurately studying cases with a non-DS phenotype but
with duplicated (trisomic) segments of Hsa21 that, therefore,
cannot be assumed to have a relevant role in DS; the final map
integrates data from both these complementary approaches,
also using available copy number variants (CNVs) (41) data to
highlight Hsa21 regions whose duplication has been found in
variation studies of the human genome in healthy subjects.
Moreover, we have not selected for the inclusion in the map, fol-
lowing accurate manual curation, any case whose description
of cytogenetic, molecular or clinical features did not allow an
unambiguous assessment of genotype–phenotype relationship.
Finally, rather than trying to identify subregions responsible for
distinct phenotypes, we focus on the diagnosis of DS itself as
the phenotype to be mapped, thus implying its most common
clinical findings: a recognizable form of ID that is also the most
serious problem for people with DS, in presence of a typical DS
facies. The fact that DS ID frequency in trisomy 21 is virtually
100% and most typical facial phenotypes are the second most
frequent signs of DS allows us to avoid confusion factors such
as variability of the presence of all other symptoms and signs,
which may be related to additive factors (allelic isoforms, CNVs,
epistasis, positional effects in cases with translocations, epige-
netics, environment) rather than the pure duplication of critical
Hsa21 portions.
The presented approach based on stringent criteria to review
cytogenetic/clinical features and on systematic map integration
led us to accurately revise data points from past analyses and to
propose a more fine delimitation at a structural level of a Hsa21
region constantly duplicated in individuals with diagnosis of DS
and thus likely associated to the most typical DS symptoms and
signs such as a recognizable form of ID and some facial
phenotypes.
Results
Partial trisomy 21 comparative map building
Following systematic bibliographic searches, 110 reports from
1973 to 2015 were identified as containing case descriptions ful-
filling cytogenetic and clinical criteria (see the following Results
section below) and then selected for the study, as described in
Table 1, Supplementary Material Tables S1 and S2 and
Supplementary Material References file.
Apart from the first case listed, published in 1965 (42) but
characterized at chromosome banding level later, the first con-
sidered report is the one published by Aula et al. (9). These
authors themselves state that cases of partial Hsa21 trisomy
‘previously reported in the literature cannot be considered’ in
the respect of identifying Hsa21 segments required for the ex-
pression of a typical DS ‘because the differential staining tech-
niques of chromosomes were not available’. A comparative
map showing the localization of segmental anomalies of Hsa21
was obtained as described in the Materials and Methods section
from 125 subjects fulfilling stringent criteria for genotype–phe-
notype mapping out of a total of 180 reported cases
(Supplementary Material Table S2). Among the six morphologi-
cal signs studied here, the most common in PT21 subjects with
DS were upslanted palpebral fissures (91.7%), epichantus (90.8%)
and flat nasal bridge (87.5%), while the most frequently absent
in PT21 subjects without DS were flat occipit/brachicefaly, broad
hands and open mouth (absent in 88.9%, 87.5% and 87.0% of
cases, respectively) (Supplementary Material Tables S2 and S3).
The frequency of all these signs was significantly different (at
P< 0.0001, except for open mouth where P¼ 0.0002) by Fisher
test between the DS and non-DS groups.
Supplementary Material Table S4 summarizes family rela-
tionships among the subjects included in the PT21 map. Only 13
subjects out of a total of 125 are relatives of an index case. In
two of these families, one relative has an opposite DS/non-DS
condition in comparison to the index case, thus enriching infor-
mation about the role of the involved Hsa21 segments. In the
other families, the related cases serve as an additional confir-
mation (similar to a ‘biological replicate’) of the genotype-phe-
notype relationship, although not totally independent.
The final picture of the comparison of candidate regions
could be derived from 88 subjects with DS, in whom trisomic re-
gions are not excluded (and therefore candidate) as responsible
for DS, while disomic regions are excluded as responsible. In the
37 subjects without DS, trisomic regions are excluded as candi-
dates for DS, while disomic regions cannot be excluded as possi-
bly responsible.
Main alterations represented in the map were: 64 (51%) cases
with reciprocal translocations involving segments of 21q; 42
(34%) cases with segmental replication of Hsa21; 7 (6%) cases
with tandem translocations involving an incomplete long arm
of the replicated Hsa21. Case summary is reported in Table 2.
Each case description was independently reviewed and
mapped by at least two authors and any discrepancy between
them in the results was discussed and reconciled. The complete
map with all details (698 sequence intervals color-labeled for all
the 125 selected cases: matrix of 87 250 data points) is available
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as Supplementary Material Table S1. A concise, sample outlook
of a portion of the map is depicted in Fig. 1.
Partial trisomy 21 comparative map analysis
Scores for association with DS for each sequence interval are
graphed in Fig. 2. Complete data for each distinct sequence in-
terval placed in the map are given in Supplementary Material
Table S1.
First, analysis of the PT21 comparative map allowed the ex-
clusion of several regions of Hsa21 as associated to DS, in partic-
ular 21p, 21q1 and 21q21. Highest scores were found in the
21q22.13 and 21q22.2 subbands (Fig. 2). Further inspection of
these regions identifies a minimal region of approximately
46 kb, located on 21q22.13 (from 37 929 229 to 37 975 580), as
having the highest scores, even when considering pure posi-
tively candidating scores not integrated with penalization/ex-
clusion scores (Supplementary Material Table S1). In addition,
although its precise boundaries are derived from a few different
informative cases (Fig. 1), the duplication of this region is shared
by all 80 DS subjects with available data about it and is absent
in all 36 non-DS subjects with available data about it, thus defin-
ing a new, highly restricted DSCR (HR-DSCR) (Supplementary
Material Table S1, Fig. 1). In detail, the most informative data for
the HR-DSCR proximal boundary came from a subject (our case
#113) analyzed by high-density oligonucleotide tiling array plat-
form, covering all regions of Hsa21 to which probes could be
uniquely mapped, with a median probe distance of 90 bp and
enabling breakpoint-mapping at 200–300 bp resolution (38),
while distal boundary was refined using CNV data as detailed
below.
There are no known genes located in the HR-DSCR.
21q22 CNV analysis
CNV analysis shows that partial duplications of Hsa21 have
been repeatedly reported in healthy subjects for regions includ-
ing whole genes, whose gain appears to therefore not be associ-
ated to DS phenotypes (Fig. 3). The 1 Mb 21q22 interval with the
least number of reported gains coincides with the one including
HR-DSCR. A more detailed analysis shows that no duplication
in the 37 674 328–37 963 130 Hsa21 interval has been described
in healthy subjects, therefore, allowing further distally narrow-
ing of the HR-DSCR, in association to PT21 data, to the 34 kb in-
terval from 37 929 229 to 37 963 130 (Supplementary Material
Table S1, Fig. 1).
In detail, the most informative data for the HR-DSCR distal
boundary came from the duplication CNV coded as structural
variant nsv1060057, supported by nssv3733448 (source: http://
dgv.tcag.ca/, explanation in the Materials and Methods section).
The experimental platform used was AffymetrixVR Genome-
Wide Human SNP Array 6.0, featuring 1.8 million genetic
markers, including more than 906 600 single nucleotide poly-
morphisms and more than 946 000 probes for the detection
of copy number variation, with an average/median intermarker
spacing of 1600 bp/680 bp, respectively (source, Affymetrix:
http://www.affymetrix.com/), that could possibly increase
the distal boundary coordinate by some hundreds of
nucleotides.
Sequence analysis
BLAST analysis of the 34 kb HR-DSCR region (1000 bp consecu-
tive stretches, BLASTN tool, searches against nr/nt database by
default parameters without filters), allowed us to find regions
with similarity typically covering 99–100% of the query with 99%
of identity in Pan troglodytes (chimpanzee) chromosome 22.
Similarity with Pongo abelii (orangutan) or other primates was
also found in some of the segments although dropped to below
50% of the query cover and below 90% of identity. No other rele-
vant similarity was observed. Attention was brought to specifi-
cally search for similarity with mouse genome, in particular
with the mouse chromosome 16, which contains the greatest
part of regions syntenic with Hsa21. Only when forcing human–
mouse selective comparison for 1000 bp consecutive stretches
and changing BLAST default parameters by adding filter for hu-
man repeats and using the more sensitive blastn algorithm
rather than default megablast, 8 small interspersed segments of
homology (from 64 bp to 552 bp, with an identity of 66–78%)
were found with mouse chromosome 16, covering in total less
than 6.1% of the HR-DSCR, or with other mouse chromosomes
(3 small segments of 68, 90 and 117 bp on chromosomes 1, 17
and 18, respectively), thus confirming the lack of relevant ho-
mology between the 33 902 bp of HR-DSCR and mouse genome.
Discussion
It is indisputable that DS is constantly associated to the pres-
ence of an excess of Hsa21 genetic material (with the very ex-
tremely rare exceptions of a few described ‘phenocopies’,
discussed below). In some subjects, the presence in excess of
only a part of Hsa21 has been demonstrated, often indeed to
Table 1. Reports of partial trisomy 21 cases from 1973 to 2015
Reports matching various PubMed queries 1322
Reports describing partial trisomy 21
apparently suitable for the study
110
1. Reports describing cases included in the map 96
2. Reports describing only cases excluded from the map 14
Reports describing partial trisomy 21 but in mosaicism 20
Reports describing partial trisomy 21 but with
X-translocation t(X;21)
3
Total of reports describing partial trisomy 21* 133
*Derived from PubMed searches plus examination of cross references.
References are listed in the Supplementary Material References file.
Table 2. Types of partial trisomy 21 reanalyzed to build the Hsa21 in-
tegrated map










t, translocation; n, any autosome involved in the translocation except Hsa21;
dup, duplication; inv, inversion; der, chromosome derived from an uncharacter-
ized alteration; ins, insertion; r, ring chromosome; rec, recombinant
chromosome.
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explain manifestation of DS in subjects with an apparently nor-
mal karyotype when studied with more simple methods. These
cases represent an invaluable natural source of knowledge
about the rational association of delimited regions/functions of
Hsa21 and DS phenotypes.
We present here the first systematic reanalysis and comparison
of all known and reported cases of PT21 with usable mapping data
(published during the last 43 years, from 1973 to 2015), enriched
with analysis of Hsa21 CNVs in healthy subjects which has become
possible in the last years. It has not been a trivial task to collect and
study this article series, mainly because of intricacies in terminol-
ogy hampering straightforward PubMed/MeSH (Medical Subject
Heading)-based searches, publication in only paper form and de-
cades ago, writing in languages different from English. We propose
that our systematic strategy to explore all the nodes of the network
made by citations in each article retrieved by PubMed searches
may have bridged the gaps remaining following the on line queries.
Our result of 125 identified cases with PT21 fulfilling stringent crite-
ria for genotype-phenotype mapping outperforms by far any at-
tempt made in the past to review previously described cases.
These cases represent a highly curated subset excluding cases with
ambiguous assessment at cytogenetic, molecular or clinical level.
In addition, the thorough reanalysis and comparison of these data
allowed correction of multiple mapping errors made in the past
thanks to the update of band boundaries as well as relative order
and exact position of many genomic markers by exploiting the lat-
est version of Hsa21 genomic coordinates and updated human
gene databases; integration of multiple analyses performed subse-
quently at different level of detail on the same subjects and re-
ported by different authors in the course of years; correction of
incongruences in clinical classification or cytogenetic characteriza-
tion and removal of cases when resolution of uncertainties or
ambiguities was not possible even after having contacted when ap-
propriate the corresponding authors of the original reports.
The minimal region whose duplication is shared by all the
subjects with DS and is not present in all the subjects without
DS revealed to be in fact a short stretch of DNA, the HR-DSCR
(Fig. 1), also showing the highest score indicating association
to DS, embedded within the traditional DSCR, confirming it
and further narrowing it, when also including CNV data in the
map (obtained from a database with >2.5 million entries iden-
tified in >22 300 human genomes) to a smaller size (34 kb, i.e.
0.07% of Hsa21) that might contain a small number of un-
known genetic determinants associated to the key manifesta-
tions of DS.
Regarding the proposal of a minimal DSCR associated to the
condition of DS, it should be noted that the scoring approach
possibly has a systematic bias depending on the level and the
detail of the type of analysis available in the reported data. A re-
gion could have a high score (Fig. 2) simply because it was often
investigated, but it could be duplicated in some subjects with-
out DS thus excluding its association to the phenotype. In this
respect, the coherence for all reported cases of the candidature
of a region in absence of any reason for its exclusion is actually
the most important fact to define its relevance (Supplementary
Material Table S1, Fig. 1). In our case, however, the two lines of
demonstration (quantity and quality) are convergent and sup-
port and strengthen each other.
Remarkably, analysis of gain (duplication) CNVs reported
through 21q22 confirmed the peculiarity of this trait, because it
appears to be spared by duplication in healthy subjects
(Supplementary Material Table S1), and it is included in a wider
zone presenting with the minimal number of gain CNVs among
all proximal and distal surrounding zones (Fig. 3). The fact that
Figure 1. HR-DSCR as highlighted by the trisomy 21-integrated map (simplified view). Only cases (columns) and CNVs strictly defining HR-DSCR limits are shown here.
Rows: Hsa21 sequence intervals (only those centered on HR-DSCR are represented here). Red¼ candidate or not excluded regions; green¼excluded regions. Levels of
overlapping among intervals are indicated by increasingly darker violet color of the coordinates; blue italics indicate coordinates overlapping (Start or End) or nesting
(Start and End) with the just previous interval (row). HR-DSCR coordinates: 37 929 229–37 963 130. Complete map is available as Supplementary Material Table S1.
2529Human Molecular Genetics, 2016, Vol. 25, No. 12 |
many PT21 cases are not well characterized with respect to
CNVs should be underlined. However, when CNVs have been
studied in detail in PT21 cases, it has been found that most of
the detected CNVs overlapped with those previously found in
unaffected individuals (38). Variability originating from CNVs
might contribute to both normal and DS phenotypes (e.g.
through silencing), both in Hsa21 (43) or in other chromosomes
(44), possibly accounting for discordant genotype–phenotype re-
lationships for certain features.
A limit of our study is that a single subject carrying a pure HR-
DSCR duplication has not been reported to date, providing positive
evidence of a critical region ‘stricto sensu’. However, in a great
number of genetic conditions, it has been widely shown that inte-
gration of data from even a few subjects with different cytogenetic
alterations and similar phenotypes has been fundamental to de-
fine a ‘critical’, ‘common minimal’, ‘minimal overlapping’, ‘mini-
mally shared’ region, leading to the narrowing of the location of
the underlying critical genetic determinants and in many cases to
their following identification (e.g. searching for ‘critical region’ or
‘minimal region’ in OMIM at http://www.omim.org/ retrieved 313
or 47 ‘phenotype description, molecular basis known’ entries, re-
spectively, and the two terms were used interchangeably).
Another clue supporting the association of HR-DSCR to the
most constant DS phenotypes, somewhat independently from
the coexistence of duplication of other specific Hsa21 regions, is
the fact that HR-DSCR is shared by subjects with DS that in the
rest of Hsa21 show absence of duplication indifferently proxi-
mally or distally to it (Fig. 1, Supplementary Material Table S1).
As a consequence of the identification of a HR-DSCR, a rele-
vant causative role in DS for genes located outside it should be
rediscussed. There are no known genes located in the HR-DSCR,
while KCNJ6 and DSCR4 are the adjacent characterized genes,
proximally and distally, respectively. Actually, the map shows
that regions both proximal and distal to the HR-DSCR may be di-
somic in subjects manifesting DS. Lack of support for the syner-
gistic roles of RCAN1 and DYRK1A, or APP, as main contributors
to many DS phenotypes had been already underlined (38).
While a relevant causative role of DYRK1A for DS has been
widely discussed (45), and while it certainly affects the develop-
ment and function of the nervous system, we have not found
evidence that it is located within the HR-DSCR, although it lies
close to it. Interestingly, a subject reported by Cetin et al. (46)
manifests DS in the absence of duplication of DYRK1A as shown
by both FISH and Array CGH (although this case has been ex-
cluded from our integrated map due to discrepancy between
the results of the two methods in another small region, between
KCNJ6 and DSCR8).
The proposed limits of the HR-DSCR add support to the likely
exclusion of a critical role, for DS as such, exerted by other
known genes whose role in DS has been often discussed,
Figure 2. Genotype–phenotype correlation in 125 cases of partial trisomy 21. The X-axis displays the score for association with DS for each sequence interval of 50 kb,
shown as median of the values assigned to each map row (Supplementary Material Table S1) that is comprised in each interval. The Y-axis represents the position
along Hsa21 (scale in Mb).
2530 | Human Molecular Genetics, 2016, Vol. 25, No. 12
although they may be involved in individual, non-constant DS
phenotypes, such as APP, SOD1, KCNJ6, ETS2 and DSCAM (33).
Currently available annotation of human genome maps does
not give any clue that HR-DSCR contains sequences associated
to known protein families, and its very small 34 kb size is lower
than the 67 kb mean size of a human protein-coding gene (as
determined by searching the recent GeneBase database (47):
mean of gene size from 17 958 ‘reviewed’ or ‘validated’ entries
in the National Center for Biotechnology Information—NCBI—
Gene April 2015 annotation release). An unknown microRNA
(miRNA) gene might represent an excellent candidate for being
a single major contributor to DS because of its pleiotropy of ac-
tion. MiR-155 miRNA overexpression has been associated to DS
through nexin 27 (48); however, no discussion was presented
about its chromosomal localization proximally on 21q21.3 at
25.5 Mb, which is far from any described DSCR.
Further detailed analysis at bioinformatic and molecular ge-
netic levels of the DSCR is needed to define its mechanism of ac-
tion in causing DS, and the task will be facilitated by the
restriction that we have presented here. If a causative role of
functional elements in this region will be shown, this will also
be of high interest in checking that they are actually silenced in
the alternative therapeutic molecular approaches aimed at
Hsa21 inactivation by XIST (49).
Our results are not inconsistent with the view that there is
not a single chromosomal region on Hsa21 responsible for most
of the DS phenotypic features (34). There are certainly different
regions mostly associated to one or the other of the DS specific
symptoms and signs (37,38). However, while none of the clinical
characteristic can be considered pathognomonic of DS, the
combination of the overall external appearance with relatively
typical ID is specific (50), so we focused on presence or absence
of DS as such. Due to the fact that ID also represents the main
real problem for persons with DS, and the most relevant for the
search of a cure which is still lacking in comparison with the
availability of treatments for heart, thyroid and other disorders
(51), our approach focused on the search for a very specific and
restricted region associated with the manifestation of the basic,
common features of DS and in particular ID appears to be well
justified. The possibility that genes outside this candidate re-
gion are also contributing to ID is not problematic: it is likely for
any imbalance of Hsa21 as well as indeed of any other chromo-
some to affect cognitive functions, considering that it is well
known that the human brain is characterized by a very high
number of active genes (52) as well as by a high prevalence of al-
ternative splicing (53).
Our approach also solves the puzzle of the apparent in-
volvement of a more proximal Hsa21 region in DS if ID is
mapped as a single phenotype: indeed, when considering DS it-
self as the phenotype, the proximal region is no longer found
because it may also be associated to ID in subjects without DS
(17), in agreement with the fact that duplication of only proxi-
mal part of 21q never results in DS phenotype (Supplementary
Material Table S1). Two subjects with ID contributed to the
identification of a proximal region for ID because they were
clustered with other cases with DS ID, but they were clearly
identified as non-DS by Park et al. (54) (cases #039 and #139 in
Supplementary Material Tables S1 and S2). It should be under-
lined here that typical DS cognitive deficits, that is delayed psy-
chomotor development, disturbance in abstract thinking and
inhibited speech development in presence of good learning,
memory, imitation and socialization abilities (50) are well rec-
ognizable both by ‘gestalt’ impression gained through clinical
experience as well as by natural history of developmental tra-
jectory (55), neuropsychological testing (56) and brain imaging
(57).
Figure 3. CNV frequency in human 21q22. The X-axis displays the number of duplication CNVs found in normal human genomes registered in the Database of
Genomic Variants (DGV) for each sequence interval of 1 Mb in the band 21q22. The Y-axis represents the position along Hsa21 (scale in Mb).
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Genomics has contributed to present the concept of a ‘per-
sonalized medicine’ (each patient is different), somewhat frag-
menting the traditional unity of nosographic entities (each
disease is equal to itself). However, the ‘splitter’ and ‘lumper’
approaches are indeed complementary and each adds knowl-
edge on its side (58). In DS, we have a well-defined cytogenetic
marker, Hsa21, so, while we see obvious phenotype differences
among each person with DS, a basic, defined common mecha-
nism for the consistent, reproducible DS ‘core’ phenotype must
exists. In several studies about DSCR, this has been ruled out by
observing that a certain single duplicated region, for instance, is
not ‘being responsible for all aspects of the phenotype’ (37),
is not ‘responsible for all or most severe DS features’ (38), and ‘is
not sufficient to cause the full DS phenotype’ (59). This view ap-
pears to be quantitative (‘all’, ‘most’ features) and does not ac-
count for the well-confirmed clinical observation that there are
some features constituting a small group but present at the
highest frequency in subjects with DS, so that a DSCR should
rather be defined as the region which ‘suffices to induce the
main phenotypic symptoms of the classic syndrome of trisomy
21’ (17) (where this region was indicated in the subbands
21q22.1 and 21q22.2, at whose boundary we find now the HR-
DSCR).
Actually, clinical observations reported in the literature (60–
62) as well as our experience in the follow-up of children with
DS (63) clearly indicate that ID and some of the craniofacial
dysmorphisms are the most frequent and constant features of
DS, so that ‘the face of a person with DS is peculiar and typical
from birth’ (50), while other symptoms and signs are less or
much less frequent and may be reasonably associated to other
Hsa21 regions contributing to the complex DS phenotype
(along with nucleotide variation, CNVs and other individual ge-
netic and possibly epigenetic features). These regions appear to
be dispensable if the crucial DS stigma are concerned, that is
fundamentally the same that allowed the historical recognition
of the nosographic entity to Dr. John Langdon Down: a ‘close
resemblance to one another in mental power’ in individuals
with typical facies he called of ‘Mongolian’ type (64) before this
inappropriate term was replaced by ‘Down syndrome’ or better
‘trisomy 21’ (65). It is not a case that, of the two most discrimi-
nating dysmorphic signs of DS found by statistical analysis
since 1976 (61), oblique eyes and flat nasal bridge, the former
was chosen by Down to initially name the syndrome itself, and
the latter has become widely used to suspect DS since prenatal
age by ultrasound scanning. The incipit of a fundamental 1990
article by Lejeune about DS pathogenesis (11) also started by
describing these signs: ‘With upward-slanting eyelids, a little
nose in a round face, and incompletely chiseled features, DS
patients look more like children than the usual child does’,
then adding that their character is ‘cheerful and affectionate,
they have a special charm easier to cherish than to describe’,
but that the condition deprives ‘the children of the most pre-
cious quality afforded by our genetic patrimony, the full power
of rational thinking’. In fact, these two facial signs typically al-
low to anticipate the full manifestation of ID, the most con-
stant feature in absolute, along with which they can be
legitimately defined ‘critical’ without necessarily being associ-
ated to a ‘full’ symptomatological spectrum. It should be also
noted that the whole Hsa21 itself is not able to cause the full
range of symptoms and signs of DS which are never all dis-
played by the same subject, are present with a great variability
even among subjects with complete trisomy 21, and may in-
volve virtually any organ. Rather, the nearly constant presence
of a few specific features (ID and facies) has been well
recognized clinically as shared by subjects with complete as
well as PT21.
With regard to the presence in our series of numerous cases
of PT21 arising from reciprocal translocation, potential posi-
tional effects should be discussed. We observe that, due to the
wide variety of translocation type or the autosome involved
along with Hsa21, the consistency of the core DS phenotype and
the coherence of the genotype–phenotype relationship with re-
gard to DS/non-DS status in both non-translocated or translo-
cated PT21 cases (Supplementary Material Tables S1 and S2)
suggests that positional effects are of little relevance for the
problem considered in this work, while they could affect sever-
ity of the core phenotypes as well as manifestation or not of
less frequent symptoms and signs.
Some of the subjects described in the works that we have ex-
amined present with a DS phenotype and no evidence of cyto-
genetic/molecular alteration; these cases are known as
phenocopies, 4 were described by McCormick et al. (28), and one
by Anneren et al. (66) and later by Ahlbom et al. (67). In these
cases, no marker was analyzed within the HR-DSCR.
Significantly, all reports of phenocopies predate the availability
of methods with high resolution at molecular level. In many
cases, as reviewed in the Introduction section, a PT21 was in-
deed discovered following a reanalysis at higher resolution of
the apparently normal chromosomes in a subject with DS. In
addition, no case of DS with a specific chromosomal/genic alter-
ation involving a chromosome different from Hsa21 has been
reported to date. Taken together, these findings are consistent
with the possibility that a very small Hsa21 region might be du-
plicated in the subjects described as ‘phenocopies’ and might be
sufficient for the expression of basic DS features. We have been
unsuccessful in the attempt to obtain samples from these sub-
jects to reanalyze their DNA by current high-resolution
methods.
While this work was in revision, two additional PT21 cases
were reported (13) in two Taiwanese fetuses without DS, who
both inherited from their respective healthy mothers a proximal
(14.3 Mb at 21q11.2q21.3) and a distal (4.4 Mb on 21q22.2q22.3)
duplication, respectively. These two cases alone allow the con-
firmation that duplication of regions covering a total of 55% of
21q, and not including 21q22.13 where we locate HR-DSCR, is
not associated to DS. Our conclusions can be in a similar way
subjected to prospective validation by accurately following the
future literature about PT21, as well as by stimulating experi-
mental reanalysis at higher resolution of the already described
cases when possible and useful.
Naturally occurring autosomal trisomy with resemblance to
DS in an animal has been described to our knowledge only in a
chimpanzee (68). Remarkably, the HR-DSCR we have identified
here has no homology as such to the mouse genome, while it is
conserved only in humans and chimpanzee. This is not incon-
sistent with a role in superior cognitive functions and with pre-
vious observations that gene content in the previously defined
larger DSCR is not identical between humans and mouse
(69,70). The DSCR4 locus (71), which is expressed in the placenta
and is the known gene located nearest to the distal boundary of
HR-DSCR, is present only in humans.
Should further analysis demonstrate critical functions for DS in
HR-DCSR, this might require a rediscussion of the usefulness of
mouse models for confuting the existence of a DSCR in mouse (72)
as well as for delimiting it (73). Actually, mouse chromosome band
16C4 presents the same loci that surround human HR-DSCR, and
in the same order (Dyrk1a, Kcnj6, Kcnj15, Erg, Ets2), but it lacks
any relevant homology with the HR-DSCR sequence itself that is
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located between KCNJ6 and KCNJ15 in humans, and such homology
cannot be found in the rest of mouse genome. Although mouse
models of DS are now available containing rearranged chromo-
somes 10, 16 and 17 in order to possibly include the full spectrum
of genes localized on Hsa21 (74) and although formally it cannot be
excluded that a similar function may be exerted in different verte-
brates by diverged sequences with no homology between them
(75), our finding contributes to bring attention to the known multi-
ple limits of genetic similarities between trisomy of Hsa21 and
mouse models (76). More generally, there is also the open problem
of the legitimacy of comparing the impairment of superior func-
tions most typical of human intelligence (77) and selectively dam-
aged in DS, such as abstraction and language, to alterations of
mouse behavior (78).
Finally, we note that while we have focused here on ID
and facies as the very basic and more constant DS features,
the framework we have built could constitute a valuable re-
source to record and map in the future other particular phe-
notypes described in the 125 cases from whom we have
obtained the integrated map, to validate in a much larger
number of cases different specific regions described as associ-
ated to, for example, congenital heart disease (37,38) or other
phenotypes with a not constant presentation in DS. A relevant
issue in this regard is the association between the duplication
of APP Hsa21 gene, encoding amyloid beta precursor protein
involved in Alzheimer disease (AD) and early onset of an AD-
like dementia in a progressively larger proportion of subjects
with DS with increasing age. While we have pointed out here
that the ID evident since the first years is a universal sign of
DS, formerly known as mental retardation and diagnosed be-
fore the age of 18 years, a form of dementia similar to AD af-
fects only a proportion of subjects with trisomy 21 (79,80),
although the risk may be upward of 70% when reaching 70
years of age, and is seen as progressive deterioration of cogni-
tive and functional abilities. No convincing relationship be-
tween severity of ID (or Intelligence Quotient—IQ—score) and
risk of AD has been found in people with DS (79). As these
facts suggest, the intimate mechanisms at the base of these
cognitive alterations must be different. An interesting finding
that emerges from our map is that 42 subjects diagnosed with
DS and with a demonstrated DS ID present with no duplica-
tion of APP (Supplementary Material Tables S1 and S2), further
underlining that APP duplication is dispensable for DS ID and
therefore that at least some core molecular mechanisms for
DS ID are distinct from those for AD. It would be very interest-
ing, on the other hand, to do an analogue mapping study cor-
relating presence or absence of APP duplication with
development or not of DS AD. However, only a few cases are
at present useful in this respect; for example, two subjects
with PT21 in absence of APP duplication did not develop AD
until at least 65 (38) or 78 (81,82) years of age (our cases #111
and #77, respectively). Articles about PT21 cases are typically
not prospectively followed by successive reports about the on-
set or not of AD, although the potential relevance of a similar
observation is clear; for example, the just published report by
Su et al. (13) states that ‘whether these two probands have
CBS- or APP-associated disorders is an issue that remains to
be closely followed up in their later lives’.
In conclusion, our results support the view that a single re-
gion associated with the manifestation of core DS features lies
on 21q22.13, appearing to be much smaller than previously sus-
pected and possibly containing currently undescribed genes
whose identification might become a priority in searching for
highly relevant targets for a cure of DS ID.
Materials and Methods
Bibliographic search
In order to retrieve all published articles related to PT21 we first
performed systematic queries on PubMed at the NCBI site
(http://www.ncbi.nlm.nih.gov/pubmed/), using a combination
of wildcards (*), Boolean operators (AND/OR) and MeSH terms.
Details of the bibliographic search are given in the
Supplementary Material Methods file.
In summary, a non-redundant set of 1322 PubMed records
(from the total of 1414 PubMed results found with all the
queries) was examined (Table 1).
All items with certain or suspect matching the aim of the
study, based on title and/or abstract, were obtained as full text.
For many articles, there was not a downloadable electronic ver-
sion, so we used library services of the University of Bologna
through ‘NILDE—Network Inter Library Document Exchange’ to
obtain scanned copies of the old paper reports. Language trans-
lation was sought, when necessary, from French or Polish.
The references cited in all the selected articles were exam-
ined, and when pointing to articles that were not identified by
PubMed searches, those articles were obtained and their refer-
ences were examined in turn. The process was repeated until
convergence, that is, as long as no further article pertinent to
the study subject was identified.
Three further articles describing PT21 cases were retrieved
by a PubMed search in 2016, following the completion of our
map and while this work was in revision. The first article, al-
though actually published in 2015 (83), was not retrieved in our
previous search performed through December 9, 2015
(Supplementary Material Methods file) because it did not men-
tion ‘Down syndrome’ (a concept that was added only after the
later MeSH terms indexing by PubMed) nor the word root ‘21q*’,
nor the expression ‘Chromosome 21’. The same subject was first
described in a 1965 report (84), which was not retrieved because
of using the term ‘mongoloid’ without containing the ‘trisom*’
word root, although all terms related to the ‘mongol’ root were
officially banned from 1961 (65). This report was not further
cited by other articles related to the matter. The subject showed
a DS phenotype although attenuated and a derivative chromo-
some 15 with a duplication of 21q spanning from 21q21.2 to the
telomer, thus consistent with our findings reported above.
The second article (85) describes a de novo duplication of
0.3 Mb in 21q22.3 associated with duplication of 0.3 Mb in
12p13.33 in a subject with ID and distinctive phenotypic fea-
tures, deriving from both of the two genetic alterations, there-
fore, it would not have been considered for our study because of
possibly confounding effects on the DS phenotype of the 12p
duplication, according to the criteria outlined in the ‘Case selec-
tion’ subsection below. The third article (13) has been cited and
discussed in the Introduction and Discussion sections above.
Case selection
An accurate selection of cases was made by reevaluation of
each report describing cases of PT21 in order to only include
cases with sufficient and unambiguous description at cytoge-
netic (and possibly molecular) and clinical level for the purpose
of creation of the integrated map.
Cytogenetic inclusion criteria were duplication of a partial
portion of 21q in absence of complex cytogenetic anomaly: tri-
somy 21 with one interstitial deletion or segmentally replicated
Hsa21; reciprocal translocations involving segments of 21q;
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tandem translocations with an incomplete long arm of the rep-
licated Hsa21. Exclusion criteria were: reciprocal or tandem
translocations and ring Hsa21 with a complete 21q; tetrasomies
of Hsa21 that have a different gene dosage in comparison with
trisomy 21; mosaic trisomy 21, less informative for determining
the phenotypic effects caused by an excess of Hsa21 segments
(10) due to effects of the cell mosaicism on the phenotype possi-
bly confounding those derived from the incomplete duplication
of 21q (16); chromosomal rearrangements involving Hsa21 and
the X chromosome, for the effects due to variable inactivation
of Hsa21 regions translocated to X (17); chromosomal alter-
ations described in leukemic cell clones.
Molecular analysis criteria were description in sufficient de-
tail of the duplicated segment boundaries: availability of at least
the banding pattern; availability of sequence data allowing
placement of sequence-tagged sites (STSs) and FISH probes on
the map; coherence among different methods when they were
used to study the same subject. Cases with incomplete descrip-
tion of the limits of the duplicated segments or with discrepan-
cies among results obtained by different methods of analysis
were not further considered.
Clinical criteria for selection of cases were: all subjects with or
without DS clinical features, as long as they present with a PT21.
Subjects were classified as ‘DS’ or ‘non-DS’ according to: explicit
statements found in the study, when authors judged DS recogniz-
able as present or absent, irrespectively of other symptoms or
signs associated to possibly concurrent aneuploidies of non-
Hsa21 chromosomal segments, or assessment of detailed pheno-
type description when present in the article. Subjects with uncer-
tain diagnosis of DS or non-DS status were excluded. This led, for
example, to exclusion of 13 cases analyzed by Lyle et al. (37) be-
cause while the description made the study of individual pheno-
types possible, which was the object of their work, it did not allow
the certain assignment of these subjects to DS or non-DS group.
Fetuses were excluded due to the impossibility of ascertaining
phenotype in detail (60). Subjects with DS phenotype but with no
visible chromosomal abnormality as well as no described molecu-
lar alteration (possible phenocopies of DS, for example (28,66,67),
where the last two references describe the same case) could not
be considered for the goal of PT21 map building.
Map framework building
First, we used the software Transcriptome Mapper (TRAM) (86)
to process human genome data downloaded from the ‘NCBI
Gene’ (http://www.ncbi.nlm.nih.gov/gene) databank and to
build an updated framework of the structure of Hsa21 based on
known Hsa21 genes. The framework was imported in a spread-
sheet table and then enriched with coordinates for single
nucleotide polymorphisms (SNPs), STSs, bacterial artificial chro-
mosome (BAC) clones, nucleotide positions determined by
Array CGH as limits of altered regions in individual subjects, cy-
togenetic band limits and key CNVs. Full details are given in the
Supplementary Material Methods file.
All the genomic coordinates related to previous versions of
the human genome sequence were converted in the matching
current coordinates on hg38 using the on line tool LiftOver
(https://genome.ucsc.edu/cgi-bin/hgLiftOver). When this was
not possible due to lack of information for the STS-related pri-
mer sequences or the location of the two primer sequences was
inconsistent, the STS was not placed on our comparative map.
When mapping of FISH data required placement of BAC clone
intervals on the map, the related coordinates were derived by
‘NCBI Clone’ (http://www.ncbi.nlm.nih.gov/clone) database.
Finally, CGH data were also converted to hg38 coordinates using
the LiftOver tool when appropriate.
In summary, spreadsheet rows represented any specific and
relevant sequence feature on Hsa21 for a total of 698 sequence
intervals (rows), providing anchor points useful to homoge-
neously map each cytogenetic feature described in the reports
of PT21 from 1973 to 2015.
Comparative map building
For each subject studied, a column on the file built as explained
above was added, representing the structure of his/her Hsa21.
Each row represented a specific sequence interval on Hsa21,
and for each subject with DS the corresponding cell was colored
following this code: red¼ trisomic, therefore, possible candidate
as causing DS; green¼disomic, therefore, excluded as causing
DS; blue¼monosomic, considered as ‘not duplicated’, therefore,
excluded as candidate; white¼ information not available with
certainty. A complementary reasoning was used to color the
cells representing sequence intervals when the subject pre-
sented cytogenetically with a segmental trisomy 21 in absence
of a typical DS picture. In particular: red¼disomic in non-DS,
therefore, not excluded as causing DS; green¼ trisomic in non-
DS, therefore, excluded as causing DS; blue¼monosomic, con-
sidered as ‘not duplicated’, therefore, indirectly not excluded as
candidate; white¼ information not available with certainty.
Headings of non-DS cases are highlighted in yellow.
Each usable detail provided in the analyzed reports has been
exploited to build the comparative map. When only cytogenetic
banding was available, the whole band has been labeled accord-
ing to the report, using the most updated correlation between
Hsa21 bands/subbands and human genome coordinates avail-
able in University of California Santa Cruz (UCSC) Genome
Browser (https://genome.ucsc.edu). In more recent works, STS,
polymerase chain reaction (PCR), FISH and CGH data were used.
All efforts were made to position each feature on the map, con-
verting the reported coordinates, usually preceding 2013, in the
matching current coordinates on hg38 (December 2013) using
the on line tool LiftOver.
Subjects repeatedly reported by different authors in the
course of years were identified, when it was possible to do so,
based on the cross references in the case description and the
data produced by different authors and methods for the same
subject were integrated on the same column of the map.
Scoring system
A score was assigned to each interval sequence substantially
following the scoring system applied by Lyle et al. (37), but at-
tributing a lower score to not excluded regions in non-DS sub-
jects due to the fact that these regions would be candidate
regions only indirectly.
A score of þ1 was assigned to each trisomic (candidate) se-
quence interval in DS subjects, while þ0.5 was assigned to diso-
mic (not excluded) intervals in non-DS subjects. A score of 1
was assigned to each sequence interval that was excluded as
candidate for DS, being disomic in DS or trisomic in non-DS sub-
jects. Monosomic regions are considered as ‘not duplicated’,
therefore, they should be excluded as candidates in DS subjects
(score ¼ 1) and indirectly not excluded in non-DS (score ¼
þ0.5). For each sequence interval, the algebraic sum of the
scores is calculated, generating the final score for the interval.
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The Excel macro and the Python scripts implementing the de-
scribed algorithms for the calculations of the scores and for
summarizing scores along Hsa21 regular intervals (Fig. 2), re-
spectively, are available upon request.
Higher scores indicate increased probability of association to
DS. Detailed partial and final scores for each interval are re-
ported in Supplementary Material Table S1 at the right of the
columns representing mapping for the 125 analyzed cases.
CNV analysis
The Database of Genomic Variants (DGV), a curated catalogue of
human genomic structural variation (87) (http://dgv.tcag.ca/), was
searched to identify any reported gain/duplication CNV in the re-
gion identified as DSCR, using hg38 map. In addition, subsequent
intervals of 1 Mb were searched to count for described gain/dupli-
cation CNVs along 21q22 sequence. For the searches, DGV data
were downloaded and imported in a FileMaker Pro (FileMaker,
Santa Clara, CA, USA) database. Structural variants were also
checked on the just released map by Sudmant et al. (88).
Phenotype recording
In recording phenotype, we focused on ID and on the most typi-
cal signs characteristic of the facies of subjects with DS, being
the particular facies, the most frequent sign associated to ID in
DS (see Introduction section). Hypotonia was not considered be-
cause it has to be observed in particular at birth and in many re-
ports, it was not recorded; in addition, its evaluation suffers of
some grade of subjectivity.
Oblique eye fissure (upslanted palpebral fissures) and flat na-
sal bridge have been recognized in the classic work by Jackson et
al. (61) as the most discriminating signs. Korenberg et al. (34) re-
ported that in their series of PT21 cases with DS ID, upslanted pal-
pebral fissures and broad hands were the most constant signs.
We recorded presence or absence, when known, of these three
mentioned signs, along with epichantus, flat occipit and mouth
permanently open for each case analyzed to build the present
map. This choice is in agreement with other reports (50,62).
The six chosen individual signs were recorded as present or
absent when this was explicitly stated, and as not available (N/
A) when no explicit statement was available. In some cases
where the picture of the subject was presented and it was clear,
it was possible to deduce the presence or absence of a pheno-
type not explicitly described or excluded in the text. Diagnosis
of presence or absence of DS was accepted as such when clearly
stated in the original article describing the case.
Supplementary Material
Supplementary Material is available at HMG online.
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